BRPI0810717A2 - sulfonato hidroxi de composto de quinona e seus usos - Google Patents

sulfonato hidroxi de composto de quinona e seus usos

Info

Publication number
BRPI0810717A2
BRPI0810717A2 BRPI0810717A BRPI0810717A BRPI0810717A2 BR PI0810717 A2 BRPI0810717 A2 BR PI0810717A2 BR PI0810717 A BRPI0810717 A BR PI0810717A BR PI0810717 A BRPI0810717 A BR PI0810717A BR PI0810717 A2 BRPI0810717 A2 BR PI0810717A2
Authority
BR
Brazil
Prior art keywords
quinone compound
hydroxy sulfonate
sulfonate
hydroxy
quinone
Prior art date
Application number
BRPI0810717A
Other languages
English (en)
Inventor
Deirdre Lowe
Erika Volckova
Judit Bartis
Manish Tandon
Marty Redmon
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of BRPI0810717A2 publication Critical patent/BRPI0810717A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
BRPI0810717A 2007-04-30 2008-04-30 sulfonato hidroxi de composto de quinona e seus usos BRPI0810717A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91497107P 2007-04-30 2007-04-30
PCT/US2008/005656 WO2008134088A1 (en) 2007-04-30 2008-04-30 Hydroxy sulfonate of quinone compounds and their uses

Publications (1)

Publication Number Publication Date
BRPI0810717A2 true BRPI0810717A2 (pt) 2016-05-24

Family

ID=39494644

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810717A BRPI0810717A2 (pt) 2007-04-30 2008-04-30 sulfonato hidroxi de composto de quinona e seus usos

Country Status (13)

Country Link
US (1) US7790765B2 (pt)
EP (1) EP2152686B1 (pt)
JP (1) JP2010526072A (pt)
KR (1) KR20100017483A (pt)
CN (1) CN101687835B (pt)
AU (1) AU2008246067B2 (pt)
BR (1) BRPI0810717A2 (pt)
CA (1) CA2685739C (pt)
DK (1) DK2152686T3 (pt)
ES (1) ES2532656T3 (pt)
MX (1) MX2009011822A (pt)
TW (1) TWI401081B (pt)
WO (1) WO2008134088A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101820873A (zh) * 2007-10-11 2010-09-01 麦仁斯有限公司 包含萘醌基化合物的微粉化粒子的药物组合物
KR101405823B1 (ko) * 2007-12-24 2014-06-12 주식회사 케이티앤지생명과학 녹내장의 치료 및 예방을 위한 약제 조성물
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
JP6091431B2 (ja) * 2011-01-31 2017-03-15 ルコラス−エム．ディー．リミテッド 医薬的使用
US9343930B2 (en) * 2012-05-25 2016-05-17 Baldor Electric Company Segmented stator assembly
WO2016006435A1 (ja) * 2014-07-10 2016-01-14 ボッシュ株式会社 モータモジュール、及びａｂｓ液圧ユニット
US10450289B2 (en) 2015-06-08 2019-10-22 University of Pittsburgh—of the Commonwealth System of Higher Education Substituted β-lapachones for treating cancer
WO2018071761A1 (en) 2016-10-13 2018-04-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Mitochondrially targeted parp inhibitor, and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0040506B1 (en) 1980-05-21 1986-08-20 Teijin Limited Reactive polymer and process for the preparation thereof
US4963565A (en) * 1986-07-30 1990-10-16 National Jewish Center For Immunology And Respiratory Medicine In vivo treatment of mycobacterial infections with 6-cyclo octylamino-5,8-quinoline quinone
US5120843A (en) * 1987-04-27 1992-06-09 Upjohn Pharmaceutically active amines
FI102273B (fi) * 1989-09-11 1998-11-13 Eisai Co Ltd Kinonijohdannaiset, niiden valmistaminen ja niiden farmakologinen käyt tö
JP3111099B2 (ja) 1991-10-31 2000-11-20 科学技術振興事業団 水溶性高分子化薬剤の製造法
US5559156A (en) * 1993-09-30 1996-09-24 Glaxo Wellcome, Inc. Method for treating animals infected with Babesia spp.
WO1994004145A1 (en) 1992-08-21 1994-03-03 Dana Farber Cancer Institute Treatment of human viral infections
US5672607A (en) * 1993-01-29 1997-09-30 The United States Of America As Represented By The Department Of Health And Human Services Antiviral naphthoquinone compounds, compositions and uses thereof
GB2282384B8 (en) 1993-08-18 1997-09-04 Europ Economic Community Drug delivery agents incorporating mitomycin
EP0640609A1 (en) * 1993-08-24 1995-03-01 Ono Pharmaceutical Co., Ltd. Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5763625A (en) * 1995-04-25 1998-06-09 Wisconsin Alumni Research Foundation Synthesis and use of β-lapachone analogs
US5674900A (en) * 1995-06-06 1997-10-07 Shaman Pharmaceuticals, Inc. Terpenoid-type quinones for treatment of diabetes
US6245807B1 (en) * 1995-08-24 2001-06-12 Dana-Farber Cancer Institute Treatment of human prostate disease
US5824700A (en) * 1996-02-20 1998-10-20 Wisconsin Alumni Research Foundation Ortho-quinone derivatives novel synthesis therefor and their use in the inhibition of neoplastic cell growth
CN1304058C (zh) 1996-03-12 2007-03-14 Pg－Txl有限公司 水溶性紫杉醇产品
AU2411197A (en) 1996-04-30 1997-11-19 Affymax Technologies N.V. Methods for the synthesis of fmoc protected amines
DE60031268T2 (de) * 1999-04-14 2007-05-24 Dana-Farber Cancer Institute, Inc., Boston Verfahren und zusammansetzung zur behandlung von krebs
IL146126A0 (en) 1999-04-30 2002-07-25 Slil Biomedical Corp Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
US6376470B1 (en) * 1999-09-23 2002-04-23 Enzon, Inc. Polymer conjugates of ara-C and ara-C derivatives
BRPI0014652B1 (pt) 1999-10-12 2016-08-09 Cell Therapeutics Inc fabricação de conjugados de agente terapêutico-poliglutamato
HUP0204562A2 (hu) 2000-03-17 2003-04-28 Cell Therapeutics, Inc. Poliglutaminsav-kamptotecin konjugátumok, eljárás előállításukra és ilyen konjugátumokat tartalmazó gyógyászati készítmények
EP1387677A2 (en) 2000-11-07 2004-02-11 Dana-Farber Cancer Institute, Inc. Method of treating hematologic tumors and cancers using beta lapachone
US6458974B1 (en) * 2001-01-25 2002-10-01 Cyclis Pharmaceuticals, Inc. Synthesis of β-lapachone and its intermediates
US6962944B2 (en) * 2001-07-31 2005-11-08 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US7074824B2 (en) * 2001-07-31 2006-07-11 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
CZ293787B6 (cs) 2001-12-20 2004-07-14 Zentiva, A.S. pH senzitivní polymerní konjugáty antracyklinového kancerostatika pro cílenou terapii
US6890950B2 (en) 2002-04-23 2005-05-10 Case Western Reserve University Lapachone delivery systems, compositions and uses related thereto
US6608076B1 (en) * 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
AU2003251904A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
BR0316296A (pt) 2002-11-18 2005-12-13 Arqule Inc Compostos lapacone e seus métodos de uso
WO2005082357A1 (en) 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treating hematologic tumors
JP2007523190A (ja) 2004-02-20 2007-08-16 アークル・インコーポレーテツド 肺癌の治療のためのβ−ラパコンの使用
EP1877097B1 (en) * 2004-08-11 2012-06-20 Arqule, Inc. Aminoacid conjugates of beta-lapachone for tumor targeting
US8614228B2 (en) * 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
WO2006128120A2 (en) 2005-05-26 2006-11-30 Arqule, Inc. Novel lapachone compounds and methods of use thereof

Also Published As

Publication number Publication date
CN101687835B (zh) 2015-08-19
MX2009011822A (es) 2010-01-14
US20090028952A1 (en) 2009-01-29
EP2152686B1 (en) 2014-12-17
HK1139411A1 (en) 2010-09-17
KR20100017483A (ko) 2010-02-16
DK2152686T3 (en) 2015-01-12
CN101687835A (zh) 2010-03-31
CA2685739A1 (en) 2008-11-06
WO2008134088A1 (en) 2008-11-06
US7790765B2 (en) 2010-09-07
AU2008246067B2 (en) 2011-10-20
EP2152686A1 (en) 2010-02-17
TW200913986A (en) 2009-04-01
JP2010526072A (ja) 2010-07-29
TWI401081B (zh) 2013-07-11
CA2685739C (en) 2016-06-14
ES2532656T3 (es) 2015-03-30
AU2008246067A1 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
BRPI0909185A2 (pt) Derivado de vitamina e e seus usos
BRPI0908853A2 (pt) composto oligopeptídicos e seus usos
BRPI0813244A2 (pt) Compostos e seus usos 708
BRPI0908268A2 (pt) compostos do inibidor de raf e seus métodos de uso
BRPI0913640A2 (pt) substâncias policrômicas e seus usos
BRPI0910746A2 (pt) reticuladores e seus usos
BRPI0817234A2 (pt) Análogos de azacitidina e seus usos
BRPI0921862A2 (pt) inibidores de raf e seus usos
BRPI0817881A2 (pt) Compostos orgânicos e seus usos
PT2473528E (pt) Formulações estáveis de polipéptidos e seus usos
BRPI0810717A2 (pt) sulfonato hidroxi de composto de quinona e seus usos
BRPI1011384A2 (pt) pro-proteinas e seus metodos de uso
BRPI0809103A2 (pt) composições de magnésio e seus usos
BR112012000660A2 (pt) compostos heterociclos e seus usos
BRPI0710878A2 (pt) Compostos orgânicos e seus usos
BRPI0906387A2 (pt) Anticorpos alfa 5 - beta 1 e seus usos
BRPI1005292A2 (pt) composição de decapagem e uso da composição
BRPI0906980A2 (pt) Composição de derivados e maleatados
BRPI0814694A2 (pt) novas esterases e seu uso
BR112012018329A2 (pt) agentes de coloração e métodos de uso destes
BRPI0906498A2 (pt) Anticorpo ron e seus usos
BRPI0906518A2 (pt) Formas cristalinas do dimetóxi docetaxel e seus processos de preparação
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
CR10815A (es) Nuevos derivados de isoquinolina e isoquinolinona sustituidos
BRPI0916269A2 (pt) dispositivo de modificação de tecido e seu método de uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements